We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by Hospital Universitari Vall d'Hebron Research Institute.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01091012
First Posted: March 23, 2010
Last Update Posted: September 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hospital Universitari Vall d'Hebron Research Institute
  Purpose
The main objective is to validate the safety and efficacy of intravenous and oral sildenafil in the acute vasodilator test in patients with persistence of, at least, moderate pulmonary hypertension after valvular surgery successfully, with a correct left ventricular function and no valvular disease hemodynamically significant.

Condition Intervention Phase
Pulmonary Hypertension Drug: Sildenafil 20mg oral vs Sildenafil 10mg intravenous Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Study About Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension, at Last Moderate and Secondary at Valve Disease(Corrected With a Normally Functioning Prosthesis).

Resource links provided by NLM:


Further study details as provided by Hospital Universitari Vall d'Hebron Research Institute:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: one day per patient ]
    The main efficacy parameter is the effect on pulmonary vascular vasodilation quantified as decreased Pulmonary Vascular Resistance.


Estimated Enrollment: 30
Study Start Date: September 2011
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sildenafil 20mg oral Drug: Sildenafil 20mg oral vs Sildenafil 10mg intravenous
2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
Other Name: REVATIO oral vs REVATIO intravenous
Sildenafil 10mg intravenous Drug: Sildenafil 20mg oral vs Sildenafil 10mg intravenous
2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
Other Name: REVATIO oral vs REVATIO intravenous

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients clinically stable, at least 1 year after the completion of successful valve surgery, with persistent pulmonary artery systolic pressure> 50 mmHg,
  • normal left ventricular function and no significant valvular disease in 2 separate Doppler ultrasound studies at least 1 month.

Exclusion Criteria:

  • Patients with other cardiac and noncardiac diseases will be excluded.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01091012


Contacts
Contact: Enric Domingo, Promotor 00-34-93-2746455 edrcg@hotmail.com

Locations
Spain
Vall Hebron Hospital Recruiting
Barcelona, Spain, 08035
Contact: Enric Domingo, Physician    00-34-93-2746455    edrcg@hotmail.com   
Principal Investigator: Enric Domingo, Physician         
Sub-Investigator: Antonio Roman, Physician         
Sub-Investigator: Rio Aguilar, Physician         
Sub-Investigator: Carlos Bravo, Physician         
Sub-Investigator: Gisela Teixidor, Physician         
Sub-Investigator: Josep Guindo, Physician         
Sub-Investigator: Christian Arredondo, Physician         
Sponsors and Collaborators
Hospital Universitari Vall d'Hebron Research Institute
Investigators
Principal Investigator: Enric Domingo, Promotor Vall Hebron Hospital
  More Information

Responsible Party: Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier: NCT01091012     History of Changes
Other Study ID Numbers: DOM-SIL-2009
2009-012005-19 ( EudraCT Number )
First Submitted: March 2, 2010
First Posted: March 23, 2010
Last Update Posted: September 11, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents